CJC 1295 without DAC
$13.09 – $65.45
CJC-1295 vs Ipamorelin: Research Comparison
Reference comparison for laboratory researchers. All material on this page is for in-vitro and investigational research only.
| CJC-1295 (no DAC) | Ipamorelin | |
|---|---|---|
| Compound class | GHRH analog | Growth hormone secretagogue (ghrelin receptor) |
| Pathway | GHRH receptor | Ghrelin receptor |
| Molecular type | Peptide analog | Peptide |
| Research use | Growth-hormone-axis research | Growth-hormone-axis research |
Ipamorelin
$13.60 – $68.00
Key Differences
- CJC-1295 (no DAC) acts via the GHRH pathway; ipamorelin acts via the ghrelin (GHS) pathway. They engage different upstream receptors.
- They are often studied together in growth-hormone-axis research because the pathways are complementary, not identical.
Evidence and Limitations
Clinical research: both have published research on growth-hormone-axis signaling; CJC-1295 no DAC refers to the short-acting variant without the drug-affinity complex.
Limitations: statements about combined use reflect research design, not a recommended regimen. No dosing or combination protocol is provided.
Research Notes
Browse the Muscle Growth / HGH category, or view batch documentation for CJC 1295 without DAC and Ipamorelin. All AminoForge material is supplied as a lyophilized research vial with an independently HPLC-verified batch record, for laboratory research use only.